This collaboration is part of 2-year UK government-funded project to bring RxSelexTM closer to patients
Amsterdam UMC and AlphaBiomics Ltd., a United Kingdom (UK)-based precision medicine company, have initiated a collaboration to personalize care in patients suffering from inflammatory bowel disease (IBD).
IBD patient response to biologics therapy is highly variable, with some patients receiving long-term benefits, while others respond temporarily or not at all. At the same time, biologics therapy can be accompanied by significant side-effects. To predict which IBD patients will benefit from biologics therapy, AlphaBiomics has developed a non-invasive, stool microbiome-based diagnostic test (RxSelexTM).
To validate RxSelexTM, AlphaBiomics will collaborate with Professor Geert D’Haens and his team at the Amsterdam UMC Department of Gastroenterology who are world-renowned experts in the care of IBD patients and the rigorous evaluation of the efficacy and safety of IBD therapies.
IBD patients at Amsterdam UMC recruited to the study will be asked to collect a stool sample prior to starting biologics therapy and their therapy response will be carefully recorded over a period of 6 months. Individual patient response as predicted by RxSelexTM from stool samples will be compared against the actual outcomes.
This 2-year project is funded by the UK National Institute for Health Research (NIHR). The project aims to carry out crucial steps needed to bring RxSelexTM to physicians and patients, such as the final development of the laboratory tests and computer programs, alignment with patient wishes and implementation in and adoption by healthcare systems.
Haermonics, een spin-off van Amsterdam UMC, heeft de effectiviteit en veiligheid bewezen van het spoelen van het hartzakje na een openhartoperatie. Een experimentele opstelling zorgde voor significant minder bloedingsgerelateerde complicaties. BOM Brabant Ventures en GAP Technologies investeren in het bedrijf voor de verdere ontwikkeling van de apparatuur en de disposables. Haermonics blijft samenwerken met Amsterdam […]News
Fitsurance and how they ‘pivot’ during COVID-19, as a VU ‘personal health’ startup All was lost (well, almost) After a great pilot-project in Zeeland, where we measured runners on the beach, to see what a 3-day running event did with runners’ health, we stepped up our efforts to prepare for 2020, in order to make […]News
Chris Slootweg (UvA) has been awarded an IXAnext Physics2Market grant for his work to use sodium borohydride as a carrier of hydrogen. For his expertise on the energy transition, especially in the field of hydrogen Slootweg has been invited to participate in the round-table discussion on the energy transition. Regeneration protocol to release hydrogen Hydrogen […]News